Icon times
IPCA Laboratories Q1FY22 Conference Call Highlights

IPCA Laboratories Q1FY22 Conference Call Highlights

Published on 09 August 2021 Views 22 Comments 1

Financial Highlights

  • Gross operating revenue stood at 1566 crores rising tepid 2% YOY from 1534 crores & showing a substantial growth of 40% QOQ because of strong growth in domestic formulations & institutional exports with a decline of around 19% in API business YOY
  • Expenses stood at 1149 crores rising 21% YOY from 886 crores & rising 30% QOQ
  • EBITDA stood at 438 crores declining YOY 27% from 600 crores but rising 76% QOQ.
  • EBITDA margin stood at 28% declining 11% YOY due to higher material costs & higher sale of lower margin products but rising 6% QOQ
  • Finance Cost stood at 1.8 crores declining 33% from 2.7 crores
  • Depreciation stood at 56 crores rising 10% from 51 crores YOY & 7% QOQ
  • PAT stood at 307 crores rising declining 31% YOY but rising 91% QOQ
  • PAT margin stood at 20% declining 9% YOY but rising 6% QOQ due to higher finance cost, employee expenses & other expenses

Business Highlights

  • Domestic formulations grew 25% YoY, while Q1FY21 also included | 54 crore of domestic HCQ(Hydroxichloroquine) business
  • Segment wise YoY growth: Pain-management (36%), cardio & antidiabetic (14%), anti-bacterial (177%), dermatology (89%), antimalarial (95%), cough & cold (83%)
  • Gross margins were affected by product mix sold in Q1FY22 (antibacterial, cough & cold and anti-malarial have low margins) and higher material cost
  • Price hiked by 6% this year against an average of 4% every year
  • Field force has returned post lockdown, which has increased promotional activities
  • Management guided for 16-18% growth in domestic business for FY22
  • Branded exports were mixed with CIS(Commonwealth of Independent States) market impacted by currency movement, Myanmar market disturbed while South African business performing well. Management guided for 12% growth in FY22
  • Generics was affected as Paracetamol prices have increased and buying levels are low. Management guided for 8-10% growth in FY22
  • UK business grew at 15% YoY with the company starting to market in its own brand name. The management guided for 10-12% growth in the next three to four years, while Europe is expected grow faster
  • US traction will take longer than earlier estimated due to USFDA import alerts for the Ratlam facility that is the only API source for Silvassa and Pithampur formulations plants along with Silvassa and Pithampur (Indore) plants that are specifically earmarked for the US business, besides third-party sales. However, sustained traction from branded and generics exports sales with a revival in EU is expected to mitigate the US void as per the management
  • Capex in API facilities got delayed due to Covid. Devas is expected to be operational in FY23 while Ratlam facility will be operational by Q3FY22. API capacity will increase by 20% post completion of both projects.
  • Management guided for 10% growth in API business foe FY22
  • EBITDA margins guidance was 25% for FY22 and management expects trend to get better
  • Capex – Rs 400 crore for next two to three years
  • Company plans to exhaust MAT credit in next 2 years (FY22 & FY23: 17%-18%) and post that lower tax regime with tax rate of 25%.
Attachments
File Name
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs 7499/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

LATEST UPDATE

premium Premium
free Free
Read More

REPORTS


Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya